Journal article
Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4
Abstract
BACKGROUND: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and OATP1B3). We studied whether concurrent use of clarithromycin and a statin not metabolized by CYP3A4 was associated with an increased frequency of serious adverse events.
METHODS: Using large health care databases, we studied a population-based cohort of older adults (mean age 74 years) who …
Authors
Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S
Journal
Canadian Medical Association Journal, Vol. 187, No. 3, pp. 174–180
Publisher
Joule
Publication Date
February 17, 2015
DOI
10.1503/cmaj.140950
ISSN
0820-3946
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Acute Kidney InjuryAgedAged, 80 and overClarithromycinCytochrome P-450 CYP3A InhibitorsDrug InteractionsFatty Acids, MonounsaturatedFemaleFluorobenzenesFluvastatinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperkalemiaIndolesLiver-Specific Organic Anion Transporter 1MaleOrganic Anion TransportersOrganic Anion Transporters, Sodium-IndependentPravastatinPyrimidinesRetrospective StudiesRhabdomyolysisRosuvastatin CalciumSolute Carrier Organic Anion Transporter Family Member 1B3Sulfonamides